Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Short Interest Update

Posted by on Jul 30th, 2026

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX – Get Free Report) was the recipient of a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 156,280 shares, a drop of 40.3% from the June 30th total of 261,876 shares. Based on an average daily volume of 39,970 shares, the days-to-cover ratio is currently 3.9 days. Approximately 8.8% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on QNRX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Monday, July 20th. ThinkEquity initiated coverage on shares of Quoin Pharmaceuticals in a report on Monday, June 15th. They issued a “buy” rating on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold”.

Check Out Our Latest Report on Quoin Pharmaceuticals

Hedge Funds Weigh In On Quoin Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Quoin Pharmaceuticals by 649.6% in the fourth quarter. GAMMA Investing LLC now owns 2,084 shares of the company’s stock valued at $30,000 after purchasing an additional 1,806 shares during the period. Simplify Asset Management Inc. purchased a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $252,000. AIGH Capital Management LLC acquired a new stake in shares of Quoin Pharmaceuticals during the 4th quarter valued at approximately $712,000. ADAR1 Capital Management LLC purchased a new stake in shares of Quoin Pharmaceuticals during the 4th quarter worth approximately $840,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Quoin Pharmaceuticals in the 4th quarter worth approximately $863,000. 8.63% of the stock is owned by institutional investors and hedge funds.

Quoin Pharmaceuticals Price Performance

NASDAQ QNRX traded down $0.04 on Thursday, hitting $4.24. 755 shares of the company’s stock were exchanged, compared to its average volume of 151,098. The firm has a market cap of $8.52 million, a price-to-earnings ratio of -0.14 and a beta of 1.52. The firm’s 50-day moving average price is $4.51 and its two-hundred day moving average price is $6.57. Quoin Pharmaceuticals has a fifty-two week low of $3.25 and a fifty-two week high of $41.80.

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.77) EPS for the quarter, beating the consensus estimate of ($2.17) by $0.40. On average, research analysts predict that Quoin Pharmaceuticals will post -7.38 earnings per share for the current fiscal year.

Quoin Pharmaceuticals Company Profile

(Get Free Report)

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.

Featured Stories

Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.